The treatment of hormone refractory prostate cancer

Comprehensive Therapy

Volumn 22, Issue 2, 1996, Pages 81-87

  Panvichian, Ravat ^a   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; FLUOROURACIL; FLUTAMIDE; FOSFESTROL; KETOCONAZOLE; LIAROZOLE; MITOGUAZONE; MITOMYCIN C; SURAMIN; TRIMETREXATE; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER HORMONE THERAPY; CANCER SURVIVAL; GYNECOMASTIA; HEART FAILURE; HUMAN; PROSTATE CANCER; REVIEW; SKIN TOXICITY; STOMATITIS; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; SURAMIN; VINBLASTINE;

EID: 0029965370     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Wingo PA, Tong T, Bolden S. Cancer Statistics. CA Cancer J Clin. 1995;45:8-30.
2. Kantoff PW. New agents in the therapy of hormone-refractory patients with prostate cancer. Semin Oncol. 1995;22(suppl 1):32-34.
3. Murphy GP, Slack NH. Response criteria for prostate cancer in the United States: National Prostatic Cancer Project. Prostate. 1980;1:375-382.
4. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013-1021.
5. Kelly WK, Scher HI, Mazumdar M, Vlamis V, Schwartz M, Fossa SD. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11: 607-615.
6. Sella A, Kilbourn R, Amato R, Bui C, Zukiwski AA, Ellerhorst J, Logothethis C. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer, J Clin Oncol. 1994;12:683-688.
7. Seidman AD, Scher. HI, Petrylak DP, Dershaw DD, Curley T: Estramustine and vinblastine: use of prostatic specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol. 1992;147:931-934.
8. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol. 1992;10:881-889.
9. Ishikawa S, Soloway MS, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostatic cancer. J Urol. 1989;141:1139-1142.
10. Petrylak DP, Scher HI, Zhaohai L, Li Z, Myers CE, Geller NL. Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostate cancer treated with single-agent chemotherapy. Cancer. 1992;70:2870-2878.
11. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol. 1993; 11:2167-2172.
12. Hussain M, Wolf M, Marshall E, Crawford ED, Eisenberger M. Effects of continued androgen deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report. J Clin Oncol. 1994;12:1868-1875.
13. Dawson NA, Kobayashi K, Vogelzang NJ. Recent therapeutic advances in "hormone-refractory" metastatic prostate cancer. In: Dawson, NA, Vogelzang, NJ, eds. Prostate Cancer. New York, NY: Wiley-Liss; 1994:235-260.
14. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71(suppl 3):1098-1109.
15. Kreis W. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer. Cancer Invest. 1995;13(3):296-312.
16. Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol. 1992;10:1754-1761.
17. Pienta KJ, Getzenberg RH, Coffey DS. Cell structure and DNA organization: CRC Rev: Critical Reviews in Eukaryotic Gene Expression. 1991;1:355-385.
18. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol. 1995; 13:2174-2186.
19. Reyno LM, Egorin MJ, Eisenberger MA, et al. Development and validation of a pharmacologically based fixed dosing scheme for suramin. J Clin Oncol. 1995;13:2187-2195.
20. Kobayashi K, Yokes EE, Vogelzang NJ, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol. 1993;13: 2196-2207.
21. Kelly WK, Scher H, Bajorin, et al. The contribution of hydrocortisone to the observed response proportions of suramin. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1994;13:A710. Abstract.
22. Tew KD, Stearns,ME. Estramustine - a nitrogen mustard/steroid with antimicrotubule activity. Pharmacol Ther. 1989;43:299-319.
23. Pienta KJ, Redman BG, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol. 1994;12:2005-2012.
24. Hussain MH, Pienta KJ, Redman BG, Cummings GD, Flaherty LE. Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer. 1994;74:100-103.
25. Roth B, Yeap B, Wilding G, Kasimis B, McLeod D, Loehrer P. Taxol (NSC 125973) in advanced hormone-refractory prostate cancer: An ECOG phase II trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1992;11:A598. Abstract.
26. Speicher LA, Barone L, Tew KD. Combined microtubule activity of estramustine and Taxol in human prostatic carcinoma cell lines. Cancer Res. 1992;52:4433-4440.
27. Hude G, Nathan F, Chapman S, Greenberg R, McAleer C. Combined antimicrotubule therapy of metastatic prostate cancer with 96-hr paclitaxel and estramustine: Activity in hormone-refractory disease. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995;14:237.